Filing Details

Accession Number:
0001104659-24-094013
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-28 16:31:58
Reporting Period:
2024-08-26
Accepted Time:
2024-08-28 16:31:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM Pharmaceutical Preparations (2834) 462159271
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1873517 J. Pamela Cramer 222 Berkeley Street
12Th Floor
Boston MA 02116
Chief Human Resources Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-26 3,200 $19.02 16,700 No 4 M Direct
Common Stock Disposition 2024-08-26 3,200 $50.01 13,500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to buy) Disposition 2024-08-26 3,200 $0.00 3,200 $19.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,536 2031-07-25 No 4 M Direct
Footnotes
  1. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024.
  2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  3. The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.